[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthenia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,74,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100642856","silkworm-pupa-powder-improves-alzheimers-disease-100642856",false,"NCT07638449","Silkworm Pupa Powder Improves Alzheimer's Disease","A Prospective, Single-Arm Study Evaluating Silkworm Pupa Powder in Improving Alzheimer's Disease Among Patients","Inclusion Criteria:\n\n* Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. Disease severity is classified as mild to moderate, defined as a Mini-Mental State Examination (MMSE) total score of 0-24 points, inclusive, at both screening and baseline.\n* Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity):\n* Aβ positivity: Plasma Aβ42\u002F40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1).\n* Tau positivity: Plasma p-tau217 ≥2.5 pg\u002FmL (or CSF p-tau181\u002FAβ42 ratio ≥0.02).\n* Age 50 to 90 years (inclusive), male or female, with at least a primary school education.\n* Stable medication use: If receiving approved AD therapies (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), doses must remain stable for ≥12 weeks prior to baseline. Treatment-naïve participants are also eligible. All other permitted non-AD related concomitant medications must remain stable for ≥4 weeks prior to baseline unless otherwise specified.\n* Hachinski Ischemia Scale (HIS) total score ≤4.\n* Geriatric Depression Scale-15 (GDS-15) total score ≤4.\n* Neuroimaging evidence: Screening CT\u002FMRI showing age-related brain changes or cerebral atrophy.\n* Participant has a stable and reliable caregiver, as confirmed by the investigator.\n* Written informed consent must be provided by the participant or, if the participant lacks decision-making capacity, by a legally authorized representative (in accordance with local laws, regulations, and customs). Participants must agree to provide peripheral blood, stool, and urine samples during the study for biomarker analysis.\n\nExclusion Criteria:\n\n* Diagnosis of dementia other than Alzheimer's disease (AD) or other central nervous system disorders.\n* Unstable vital signs accompanied by abnormalities in cardiac, pulmonary, hepatic, renal, or other organ functions.\n* Abnormally low folate and\u002For vitamin B12 levels, or evidence that hypothyroidism has caused or exacerbated the participant's dementia. Abnormal syphilis test results.\n* Comorbid psychiatric disorders.\n* Long-term alcoholism or substance abuse that may compromise the evaluation of treatment efficacy.\n* Intolerance or allergy to the study medication (silkworm pupa powder).\n* Abnormalities detected on cranial MRI, including ischemic or hemorrhagic infarctions, hydrocephalus, or brain tumors.\n* Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within 12 months or at present.\n* Geriatric Depression Scale-15 (GDS-15) score \\>4 at screening.\n* Any other inadequately controlled condition (e.g., cardiac, respiratory, renal, or gastrointestinal disorders affecting absorption, such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.\n* Administration of any new chemical entity in an AD clinical study within 6 months prior to screening.\n* Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or electrocardiogram (ECG) requiring further investigation, treatment, or posing risks to study procedures or safety.\n* Participation in a clinical study involving therapeutic monoclonal antibodies, antibody-derived proteins, immunoglobulin therapy, or vaccines within 6 months prior to screening.\n* Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapy and any BACE inhibitor therapy).\n* Any inadequately controlled immune disorder, or immune disease requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study.\n* Inadequately controlled bleeding disorders (including platelet count \\\u003C50,000 or INR \\>1.5 for participants not on anticoagulants, e.g., warfarin). Participants on anticoagulants must have their anticoagulation status optimized and receive a stable dose within 4 weeks prior to screening. Participants receiving anticoagulant therapy must not participate in cerebrospinal fluid (CSF) assessments.\n* Participation in another concurrent silkworm pupa powder intervention study conducted at the same study center.","ALL","50 Years","90 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if silkworm pupa powder works to treat Alzheimer's disease in patients. It will also learn about the safety of silkworm pupa powder, and its effect on patients' nutritional and frailty status. The main questions it aims to answer are:\n\n* Does silkworm pupa powder improve cognitive function and daily living abilities?\n* Does silkworm pupa powder improve nutritional status and frailty?\n* What medical problems do participants have when taking silkworm pupa powder?\n\nResearchers will evaluate the treatment by comparing the participants' conditions after taking the powder to their baseline conditions (a single-arm study without a placebo) to see if silkworm pupa powder works to treat Alzheimer's disease.\n\nParticipants will:\n\n* Take silkworm pupa powder every day for 12 weeks\n* Visit the clinic once every 4 weeks for checkups and tests\n* Use an electronic punch-card system daily and report any symptoms",[27,28,29,30],"Alzheimer Disease","Sarcopenia","Asthenia","Frailty",[32,33,34,35,36],"Silkworm Pupa Powder","Nutritional Status","Frailty State","Cognitive Function","Dietary Supplement","NOT_YET_RECRUITING","2026-06-04",{"date":40,"type":41},"2026-06-10","ACTUAL",{"date":43,"type":21},"2026-06-01",{"date":45,"type":21},"2027-12-31",{"name":47,"class":48},"Zhejiang Provincial Tongde Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":73,"locationsCount":49},"100585139","silkworm-pupa-powder-improves-dementia-100585139","NCT06898476","Silkworm Pupa Powder Improves Dementia.","A Prospective, Double-Blind, Randomized Controlled Trial Evaluating Silkworm Pupa Powder Versus Placebo in Improving Alzheimer's Disease Among Patients","Inclusion Criteria:\n\n* Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, with disease severity classified as mild, moderate, or severe (i.e., Mini-Mental State Examination \\[MMSE\\] total score between 0 and 24 points \\[inclusive\\] at screening and baseline).\n* Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity):\n* Aβ positivity: Plasma Aβ42\u002F40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1).\n* Tau positivity: Plasma p-tau217 ≥2.5 pg\u002FmL or CSF p-tau181\u002FAβ42 ratio ≥0.02.\n* Age: 50 to 90 years of age (inclusive), with at least a primary school education. Both males and females are eligible.\n* Stable medication use: If receiving approved AD therapies (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), doses must remain stable for ≥12 weeks prior to baseline. Treatment-naïve participants are also eligible. All other non-AD-related permitted concomitant medications must remain stable for ≥4 weeks prior to baseline unless otherwise specified.\n* Hachinski Ischemia Scale (HIS) total score ≤4.\n* Geriatric Depression Scale-15 (GDS-15) total score ≤4.\n* Neuroimaging evidence: Screening CT\u002FMRI showing age-related brain changes or cerebral atrophy.\n* Caregiver availability: Participant has a stable and reliable caregiver, as confirmed by the investigator.\n* Informed consent: Written informed consent must be provided by the participant or, if the participant lacks decision-making capacity, by a legally authorized representative (in accordance with local laws, regulations, and customs). Participants agree to provide peripheral blood, stool, and urine samples during the study for biomarker analysis.\n\nExclusion Criteria:\n\n* Diagnosis of dementia other than Alzheimer's disease (AD) or other central nervous system disorders.\n* Unstable vital signs accompanied by abnormalities in cardiac, pulmonary, hepatic, renal, or other organ functions.\n* Abnormally low folate and\u002For vitamin B12 levels, or evidence that hypothyroidism has caused or exacerbated the participant's dementia. Participants with abnormal syphilis test results.\n* Patients with comorbid psychiatric disorders.\n* Long-term alcoholism or substance abuse that may compromise the evaluation of treatment efficacy.\n* Participants with intolerance or allergy to the study medications.\n* Abnormalities detected on cranial MRI, including ischemic or hemorrhagic infarctions, hydrocephalus, or brain tumors.\n* Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within 12 months or at present.\n* Antibiotic use:\n\n  1. Continuous antibiotic use for more than 10 days within 12 weeks prior to baseline.\n  2. Anticipated need for antibiotic treatment exceeding 10 days during the study.\n* Geriatric Depression Scale-15 (GDS-15) score \\>4 at screening.\n* Any other inadequately controlled condition (e.g., cardiac, respiratory, renal, or gastrointestinal disorders affecting absorption, such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.\n* Participation in any clinical trial involving novel chemical entities for Alzheimer's disease (AD) within 6 months prior to screening, unless confirmed to have been in the placebo group.\n* Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or electrocardiogram (ECG) requiring further investigation, treatment, or posing risks to study procedures\u002Fsafety.\n* Participation in clinical trials involving therapeutic monoclonal antibodies, antibody-derived proteins, immunoglobulin therapy, or vaccines within 6 months prior to screening, unless confirmed to have been in the placebo group.\n* Participation in clinical trials involving anti-amyloid therapies (including monoclonal antibodies or BACE inhibitors), unless confirmed to have received only placebo.\n* Uncontrolled immune disorders requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study.\n* Participants with uncontrolled bleeding disorders, including platelet count \\\u003C50,000 or INR \\>1.5 (for those not on anticoagulants, e.g., warfarin). Participants on anticoagulants must have optimized and stable dosing for ≥4 weeks prior to screening. Anticoagulated participants are excluded from cerebrospinal fluid (CSF) assessments.",{"count":58,"type":21},300,[24],"The purpose of this clinical trial is to determine whether silkworm pupa powder is effective in treating Alzheimer's disease. It will also investigate whether silkworm pupa powder can improve the nutritional and frailty status of patients with Dementia. The main questions it aims to answer are:\n\n* Will silkworm pupa powder improve the daily living conditions of patients with Alzheimer's disease?\n* Will silkworm pupa powder improve the nutritional status and frailty of Alzheimer's disease patients?\n\nResearchers will compare silkworm pupa powder with a placebo (a similar substance containing 0.5% silkworm pupa powder) to see if silkworm pupa powder can treat Alzheimer's disease.\n\nParticipants will:\n\n* Take silkworm pupa powder or placebo daily for four months;\n* Visit the clinic for check-ups and tests every four weeks;\n* Record their symptoms and various physiological indicators.",[62,28,29],"Alzheimer Disease(AD)",[27,28,64,65,66],"asthenia","nutritional status","frailty state","RECRUITING",{"date":69,"type":41},"2026-06-08",{"date":71,"type":41},"2025-04-10",{"date":45,"type":21},{"name":47,"class":48},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":49},"100597544","a-study-of-silkworm-pupa-powder-intervention-in-the-nutritional-status-of-patients-with-alzheimers-disease-100597544","NCT07059871","A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease.","A Prospective, Double-blind, Randomized Controlled Clinical Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease","AD","Inclusion Criteria:\n\n* Meet the diagnostic criteria for probable dementia due to Alzheimer's disease (AD) as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) (2024).\n* Male or postmenopausal female (without childbearing potential). Participants aged 50-90 years (inclusive), with an education level of primary school or higher.\n* Mini-Mental State Examination (MMSE) score: ≤17 for illiterate, ≤20 for primary school education, ≤22 for secondary school education, ≤23 for university education; Clinical Dementia Rating (CDR) global score \\> 2.0.\n* Activities of Daily Living (ADL) Scale score \\>0 and ≤40.\n* Nutritional Risk Screening (NRS 2002) score ≥3 at screening\u002Fenrollment.\n* Good general health status, Eastern Cooperative Oncology Group (ECOG) Performance Status score ≤3.\n* If currently receiving approved AD treatments (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), must be on a stable dose for at least 12 weeks prior to baseline, with stable cognitive assessment scores. Treatment-naïve participants for AD are eligible. Unless otherwise specified, all other permitted concomitant medications (non-AD related) must be stable for at least 4 weeks prior to baseline.\n* Availability of a stable, reliable caregiver confirmed by the investigator.\n* Voluntarily participate in the clinical study, fully understand and be informed about the study, and sign the Informed Consent Form (ICF); willing and able to comply with and complete all trial procedures. If the participant, in the investigator's judgment, lacks capacity to consent, consent must be obtained according to local laws, regulations, and customs (or signed by the patient's caregiver under the authorization of the patient's legal guardian). Agrees to provide peripheral blood, stool, and urine samples for biomarker analysis during the study.\n\nExclusion Criteria:\n\n* Dementia caused by: vascular dementia; CNS infections (e.g., AIDS, syphilis); Huntington's disease; Parkinson's disease; Lewy body dementia; traumatic brain injury-related dementia; other physical\u002Fchemical factors (e.g., drug intoxication, alcohol intoxication, carbon monoxide poisoning); significant systemic diseases (e.g., hepatic encephalopathy, pulmonary encephalopathy, hypoxic encephalopathy); intracranial space-occupying lesions (e.g., subdural hematoma, brain tumor); endocrine disorders (e.g., thyroid disease, adrenal disease); vitamin deficiencies; or dementia due to any other cause.\n* Co-existing autoimmune diseases, such as multiple sclerosis, polymyositis, myasthenia gravis, Guillain-Barré syndrome, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, vitiligo, etc.\n* Severe renal impairment: Creatinine clearance \\\u003C30 mL\u002Fmin (Cockcroft-Gault formula) or other known severe renal disease; Severe hepatic impairment: ALT or AST \\>10 times the upper limit of normal (ULN), or other known liver diseases such as acute\u002Fchronic active hepatitis, cirrhosis, etc.; Acute myocardial infarction or interventional cardiac procedure within 6 months prior to screening; Heart failure (NYHA Class III-IV); Patients with other severe primary neurological, cardiac, pulmonary, hematopoietic, endocrine system diseases, or psychiatric disorders.\n* Suspected or confirmed history of alcohol or drug abuse.\n* Life expectancy ≤3 months.\n* Pregnant or lactating women. Participants of childbearing potential (including male participants engaging in heterosexual intercourse and their female partners of childbearing potential) planning pregnancy or unwilling to use effective contraception from screening initiation until 3 months after discontinuation of the study drug.\n* Known allergy\u002Fhypersensitivity to any component of the investigational product(s).\n* Participation in another investigational drug trial within 30 days prior to screening or current participation in any other clinical trial.\n* Presence of any other severe physical or psychiatric illness or laboratory abnormality that may increase the risk associated with study participation or, in the investigator's judgment, makes the patient unsuitable for the study.\n* Clinically significant psychiatric disorders or severe psychiatric symptoms.\n* MMSE score \\>26.\n* ADL Scale score \\>40.\n* Clinically significant elevation of tumor markers, history of malignancy, or patients with tumors of undetermined nature.\n* Significant risk of suicide.\n* Chronic alcohol abuse or substance abuse that may interfere with efficacy evaluation.\n* Intolerance or allergy to the drugs used in this study.\n* Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within the past 12 months or current diagnosis.\n* Antibiotic use: a. Continuous use of antibiotics for \\>10 days within 12 weeks prior to baseline; b. Anticipated need for antibiotic treatment exceeding 10 days during the study. Any other disease (e.g., cardiac, respiratory, renal, gastrointestinal diseases potentially affecting absorption such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) not adequately controlled and stable, or any condition the investigator believes may affect participant safety or interfere with study assessments.\n* Any other clinically significant abnormality in physical examination, vital signs, laboratory tests, or electrocardiogram (ECG) that, in the investigator's opinion, warrants further investigation or treatment, or may interfere with study procedures or safety.\n* Participants with inadequately controlled hemorrhagic disorders (including platelet count \\\u003C50 x 10\\^9\u002FL or International Normalized Ratio \\[INR\\] \\>1.5 for participants not on anticoagulant therapy like warfarin).\n* Any other condition deemed by the investigator to make the participant unsuitable for study participation.",{"count":83,"type":21},200,[24],"The goal of this clinical trial is to learn if silkworm pupa powder works to improve the nutritional status of Alzheimer's disease patients. The main questions it aims to answer are:\n\n* Does silkworm pupa powder evaluate the effectiveness of silkworm pupae in improving sarcopenia, frailty and quality of life in AD patients?\n* Does silkworm pupa powder improve cognitive function in AD patients?\n\nResearchers will compare silkworm pupa powder to a placebo (a look-alike substance that contains no drug) to see if silkworm pupa powder works to improve the nutritional status of Alzheimer's disease patients.\n\nParticipants will:\n\n* Take drug silkworm pupa powder or a placebo every day for 3 months.\n* Visit the clinic once every 4 weeks for checkups and tests.\n* Keep a diary of their daily consumption.",[87,28,29],"AD - Alzheimer's Disease",[27,28,64,65],"2025-12-28",{"date":91,"type":41},"2026-01-02",{"date":93,"type":41},"2025-11-23",{"date":95,"type":21},"2026-12-30",{"name":97,"class":48},"Zhejiang Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":80,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":85,"conditions":107,"keywords":109,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":49},"100575286","a-study-of-silkworm-pupa-powder-intervention-in-the-nutritional-status-of-patients-with-alzheimers-disease-100575286","NCT06770309","A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients with Alzheimer's Disease.","A Prospective, Double-blind, Randomized Controlled Clinical Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients with Alzheimer's Disease","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for dementia caused by AD as determined by the National Institute on Aging and the Alzheimer's Disease Association (NIA-AA) (2024);\n2. Male or menopausal female (no fertility requirement), participants are 50-90 years old (inclusive) with primary school education or above;\n3. The Mini Mental State Examination (MMSE) score for illiteracy is ≤ 17 points, primary school education is ≤ 20 points, secondary school education is ≤ 22 points, and university education is ≤ 23 points; CDR\\>2.0 points;;\n4. 0 points\\\u003C 40 points ≤ the ADL Rating Scale;\n5. At the time of screening and enrollment, there was a nutritional risk score of ≥3 points (according to the NRS2002 Nutritional Risk Screening Form);\n6. In good general condition, ECOG score ≤ 3 points;\n7. If you are receiving approved Alzheimer's disease treatment, such as acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists, you must maintain a stable dose for at least 12 weeks before baseline, and the cognitive evaluation scale is stable. Participants who have not been treated for Alzheimer's disease may be enrolled. Unless otherwise noted, participants must maintain a stable dose of all other (i.e., non-Alzheimer's disease-related) permitted concomitant medications for at least 4 weeks prior to baseline;\n8. The investigator confirms that the subject has a stable and reliable caregiver;\n9. You voluntarily participate in this clinical research, fully understand and be informed about the study, and sign the informed consent form (ICF).； Willing to follow and able to complete all trial procedures. If the participant lacks the capacity to consent in the opinion of the investigator, the participant's consent shall be obtained as required by local laws, regulations, and customs. (or signed by the patient's caregiver with the authorization of the patient's guardian) during the study to agree to provide peripheral blood, feces, urine, samples for biomarker analysis.\n\nExclusion Criteria:\n\n1. Dementia caused by the following reasons: vascular dementia, central nervous system infection (such as AIDS, syphilis, etc.), Huntington's disease and Parkinson's disease, dementia with Lewy bodies, traumatic brain dementia, other physical and chemical factors (such as drug poisoning, alcohol poisoning, carbon monoxide poisoning, etc.), important physical diseases ( Such as hepatic encephalopathy, pulmonary encephalopathy, hypoxic encephalopathy, etc.), intracranial mass lesions (such as subdural hematoma, brain tumors), endocrine system lesions (such as thyroid disease, adrenal gland disease) as well as dementia caused by vitamins or any other cause;\n2. Patients with other autoimmune diseases, such as multiple sclerosis, polymyositis, myasthenia gravis, Guillain-Barré syndrome, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, vitiligo, etc.;\n3. Severe renal insufficiency: creatinine clearance rate \\\u003C 30mL\u002Fmin (Cockcroft-Gault formula).or other known severe renal insufficiency disease; Severe hepatic impairment: ALT or AST \\> 10 times the upper limit of normal, or other known liver diseases such as acute and chronic active hepatitis, liver cirrhosis, etc.; During the screening period, patients with acute myocardial infarction or interventional therapy in the past 6 months, and heart failure (patients classified as grade III-IV according to NYHA); Patients with other serious primary diseases of the nervous system, heart, pulmonary, hematopoietic system or endocrine system and psychiatric disorders;\n4. Those who suspect or have a history of alcohol or drug abuse;\n5. Estimated survival ≤ 3 months;\n6. Pregnant women or lactating women, subjects of childbearing age (including male subjects with heterosexual intercourse and their female partners of childbearing potential) who have pregnancy plans or are unwilling to take effective contraceptive measures from the beginning of screening to 3 months after discontinuation;\n7. Those who are allergic to the ingredients of known test supplies\n8. Participated in other drug clinical trials within 30 days before screening, or are participating in other clinical trials;\n9. Patients with other serious physical or psychiatric diseases or laboratory abnormalities that may increase the risk of participating in the study and who are considered by the investigator to be unsuitable for participating in this study\n10. Clinically severe mental disorder or psychiatric symptoms;\n11. Mini-Mental State Assessment Scale (MMSE) score \\> 26 points;\n12. Activity of daily living ability (ADL) rating scale \\> 40 points\n13. Patients with abnormally elevated tumor markers or a history of tumor or no clear tumor;\n14. Those who are at serious risk of suicide;\n15. Patients who are intolerant or allergic to the drugs used in this study;\n16. Clinically significant cardiovascular or cerebrovascular disease requiring treatment within 1 6 months or current diagnosis within 2 months;\n17. Use of antibiotics: a. Use of antibiotics for more than 10 consecutive days in the 12 weeks prior to baseline; b. Subjects are expected to be treated with antibiotics for more than 10 days; Any other medical condition (e.g., cardiac, respiratory, renal disease, gastrointestinal disease that may affect absorption, such as gastric cancer, gastric bypass, or recurrent diarrhea) that is not stable and adequately controlled, or that, in the opinion of the investigator, may affect the safety of the participant or interfere with study assessments;\n18. Any other clinically significant abnormality in physical examination, vital signs, laboratory tests, or ECG that, in the opinion of the investigator, requires further investigation or treatment, or may interfere with study procedures or safety;\n19. Participants with bleeding disorders that are not adequately controlled (including platelet count\\\u003C 50\\*10\\^9\u002FL or international normalized ratio \\[INR\\]\\>1.5 for participants who did not receive anticoagulation therapy, e.g., warfarin);\n20. Other circumstances that the researcher deems inappropriate to participate in this study.",{"count":20,"type":21},[24],[108,28,29],"Alzheimer Disease (AD)",[27,28,64,65],"2025-01-07",{"date":112,"type":41},"2025-01-13",{"date":114,"type":21},"2025-01-02",{"date":116,"type":21},"2025-12-31",{"name":118,"class":48},"Yanbu Ke"]